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Abstract
Background: Few data are available to assess whether a low-moderate reduction
in estimated glomerular filtration rates (eGFR) has a role per se on cardiovascular
(CV) mortality or other biomarkers such as NT-proBNP allow to explain such
association.
Methods and Findings: In a prospective study including 1,645 type 2 diabetic
subjects of the population-based Casale Monferrato Study, who had no clinical
evidence of heart failure and eGFR .45 ml/min/1.73 m2, we examined 6 years CV
mortality. Multivariate Cox proportional hazards modeling were used to estimate the
effect of NT-proBNP on the association between eGFR and mortality, independently
of baseline CV risk factors, albumin excretion rate (AER) and C-reactive protein
(CRP). During follow-up, 327 people died (149 of CV diseases) out of 8334.5 person-
years. Compared to eGFR$90 ml/min/1.73 m2, values of 60–89 and 45–59 ml/min/
1.73 m2 conferred a fully adjusted hazard ratios (HRs) of CV mortality of 1.74 (1.08–
2.82) and 1.95 (1.03–3.68), respectively. After further adjustment for NT-proBNP,
however, HRs were no longer significant (HRs 1.42, 0.83–2.42 and 1.22, 0.59–2.51).
In this model, HR for logNT-proBNP was 1.84 (1.52–2.22). Adding NT-proBNP to the
model improved the C-statistic of CV mortality from 0.79 (0.76–0.83) to 0.84 (0.81–
0.87), yielded an IDI of 0.03 (p50.02), and a NRI of 0.44 (p50.016).
Conclusions: In diabetic people a modest reduction in renal function increased 6-
year CV mortality independently of albuminuria. This association, however, was
mainly explained by the effect of NT-proBNP, that remained the strongest
OPEN ACCESS
Citation: Bruno G, Barutta F, Landi A, Cavallo
Perin P, Gruden G (2014) NT-proBNP Linking Low-
Moderately Impaired Renal Function and
Cardiovascular Mortality in Diabetic Patients: The
Population-Based Casale Monferrato Study. PLoS
ONE 9(12): e114855. doi:10.1371/journal.pone.
0114855
Editor: Gianpaolo Reboldi, University of Perugia,
Italy
Received: June 8, 2014
Accepted: November 14, 2014
Published: December 11, 2014
Copyright:  2014 Bruno et al. This is an open-
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and repro-
duction in any medium, provided the original author
and source are credited.
Data Availability: The authors confirm that all data
underlying the findings are fully available without
restriction. All relevant data are within the paper
and its supporting information files.
Funding: The authors have no support or funding
to report.
Competing Interests: The authors have declared
that no competing interests exist.
PLOS ONE | DOI:10.1371/journal.pone.0114855 December 11, 2014 1 / 11
prognostic marker for a worse CV outcome, even after adjustment for other CV risk
factors and pre-existing CVD.
Introduction
Diabetes is a leading cause of chronic kidney disease (CKD) in the Western
countries and patients with CKD are exposed to increased morbidity and
mortality as a result of cardiovascular (CV) events [1]. Early detection of CKD by
estimating glomerular filtration rate (eGFR) using creatinine-based formulas has
been suggested as a valid tool to improve patients stratification and to intensify
treatment in subgroups of diabetic patients at highest risk of CV events [2]. In
addition, a synergistic relationship between eGFR and microalbuminuria in
predicting long-term progression to end-stage renal disease (ESRD) and CV death
has been recently confirmed in large cohorts of diabetic patients [3], emphasizing
the importance of their combined assessment to improve risk prediction.
Despite the growing recognition of the relationships between kidney and CV
diseases along the cardiorenal continuum, the underlying pathophysiology
remains poorly understood. Endothelial dysfunction, cardiac remodelling, and
atherosclerosis occurs in early CKD stages and are believed to contribute to the
enhanced CV risk of patients with CKD [4]. Discovery of novel biomarkers,
mirroring these early pathogenetic events and possibly mediating the epidemio-
logical relationship between CKD and CV events, may significantly improve risk
stratification, particularly in the subgroup of type 2 diabetic patients at low-
moderate risk [5].
Human natriuretic peptides genes encode for long inactive peptides that are
processed to active peptides and equimolar concentrations of inactive fragments.
PreproBNP is converted in proBNP by removal of a 26-amino acid sequence. Pro-
BNP, which is often post-translationally O-glycosylated in the N-terminal region,
is cleaved by furin into BNP and the inactive fragment NT-proBNP [6].
Compared to BNP, NT-proBNP has a longer plasma half-life, making it a more
suitable biomarker for clinical use. Cardiac stretch causes secretion of BNP
(32aminoacid-long peptide hormone) and NT-proBNP (76 aminoacid-long
peptide) which are released in equimolar amounts into the circulation and are
physiological antagonists of the renin-angiotensin system. The N-amino terminal
fragment of the prohormone B-type natriuretic peptide (NT-proBNP) is released
from cardiomyocytes in response to ventricular wall stretch/tension and is a
sensitive marker of both left ventricular hypertrophy and volume expansion [6].
We have recently reported that NT-proBNP is also a strong independent predictor
of short-term CV mortality risk in type 2 diabetic patients, including those
without preexisting CVD [7]. NT-proBNP values are enhanced in subjects with
CKD [8], but the clinical interpretation of these results in asymptomatic patients
has been a source of controversy [9]. From a clinical point of view, it is of
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particular relevance the identification of CV predictors in the subgroup of patients
with only moderately reduced renal function. However, prospective data on the
relationship between eGFR, albuminuria, and NT-proBNP on CV mortality in
these patients are limited [10] and no data are available in type 2 diabetic patients.
In the present study, we have prospectively assessed the effect of NT-proBNP
on the association of moderately reduced eGFR levels with 6-years CV mortality,
independently of classical and new cardiovascular risk factors, including
albuminuria and plasma C-reactive protein (CRP), in a population-based cohort
of people with type 2 diabetes and eGFR .45 ml/min/1.73 m2. [11–12].
Subjects and Methods
Baseline Study
The Casale Monferrato survey was begun in 1988 with the aim of assessing the
prevalence of known diabetes in persons living in the area of Casale Monferrato,
Northern Italy (93477 inhabitants). The study design has been described in detail
elsewhere [11–13]. Briefly, persons with a previous diagnosis of diabetes
(n51967) were identified from diabetes clinics, general practitioners, hospital
discharge records, prescriptions and records of sales and reagent strips and
syringes. The completeness of ascertainment (80%) was estimated by applying
log-linear models to the capture-recapture methods, making it possible to take
into account both dependence between data sources and the heterogeneity of
patients within sources [11]. In 2000 a new survey included all the members of the
original cohort who were still alive and living in Casale Monferrato (N5860), and
in addition all the persons with a new diagnosis of type 2 diabetes (N52389), with
an estimated completeness of ascertainment of 95%. All the subjects are white. Of
the 3,249 type 2 diabetic subjects enrolled in the Casale Monferrato Study, we
excluded 1463 patients who had no samples available for NT-proBNP, 56 patients
who had clinical evidence of acute and or chronic heart failure, and 85 patients
with eGFR ,45 ml/min/1.73 m2, leading to a final cohort of 1,645 (50.6%)
patients recruited for present analyses.
The date of diabetes diagnosis was retrieved and recorded for all recruited
subjects. As described in detail elsewhere, patients were interviewed, examined,
and blood samples collected after overnight fasting [12]. Ethics approval was
obtained by the Alessandria Hospital Ethical Committee and all subjects provided
written informed consent. Blood samples were collected at the baseline
examination in 2000 in 60% of the cohort, depending on their consent to provide
further blood samples for future research purposes. Smoking status was classified
as current smoker, never smoker, ex-smoker (smoking cessation at least a month
prior to the visit). Hypertension was defined as systolic blood pressure.140 mmHg
and/or diastolic blood pressure .90 mmHg or treatment with antihypertensive
drugs. CVD was defined as a positive medical history of a CV event, including
myocardial infarction, angina pectoris, coronary artery bypass graft and stroke, and/
or ischemic changes on a resting 12-lead electrocardiogram, classified according to
NT-proBNP, eGFR and Cardiovascular Mortality
PLOS ONE | DOI:10.1371/journal.pone.0114855 December 11, 2014 3 / 11
the Minnesota Code. The WHO Rose questionnaire was also administered and
people with symptoms suggestive of CVD underwent further investigations to
confirm the diagnosis. Congestive heart failure was clinically diagnosed based on
medical history, physical examination, and drug treatment and were considered an
exclusion criteria for this analysis.
Blood samples were analysed at the Central Laboratory [12]. Triglycerides, total
cholesterol, high-density lipoprotein (HDL) cholesterol, apolipoprotein A1
(apoA1), apoB, serum creatinine, and hemoglobin A1c (HbA1c) (reference range,
3.8–5.5%) were measured by standard laboratory techniques. Low-density
lipoprotein (LDL) cholesterol was calculated from Friedewald’s formula when
triglyceride values were ,4.48 mmol/l. Glomerular filtration rate (GFR) was
estimated using the four component abbreviated equation from the MDRD Study
[14]. High-sensitivity (hs)-CRP was measured by immunoturbidimetry (Roche-
Diagnostic, coefficient of variation 50.5%). Albumin excretion rate (AER) was
measured by nephelometry (Behring Nephelometer Analyzer, Behring Institute,
Marburg, Germany, coefficient of variation: 4%) on single overnight urine
collections and categorised as either normoalbuminuria (,20 mg/min) or micro/
macroalbuminuria ($20 mg/min). Serum NT-proBNP levels were measured by a
two-site sandwich electrochemiluminescence immunoassay (Elecsys proBNP II,
Roche Diagnostic, Mannheim, Germany), using a Modular Analytics Evo analyzer
with a E170 module (Roche) as previously described [15]. The intra-assay
variation was below 3.0% and total coefficient of variation ranges between 2.2 and
5.8% in low and high ranges of NT-proBNP.
Follow-Up Study
Six years after the baseline examinations, mortality data up to December 31st,
2006 were obtained from the demographical files of towns of residence and both
hospital and autopsy records. Only one patient was lost to follow-up. Underlying
causes of death were derived and coded by two authors, according to the 9th
revision of the International Classification of Disease (ICD). Cardiovascular
mortality was defined by ICD-9 codes 390–459.
Statistical Analysis
Variables distributed normally are presented as mean and standard deviation
(SD), whereas variables with skewed distribution were analysed after natural
logarithmic transformation (triglycerides, NT-proBNP, CRP) and results
presented as geometric means. Anova test with Scheffe method for multiple
comparisons was employed to compare features of people across levels of eGFR.
Mortality rates were calculated dividing the number of deaths, occurring during
the study period, by the number of person-years of observation. Cox proportional
hazards modelling was used to estimate the hazard ratios (HRs) and 95%
confidence intervals (95% CI) of cardiovascular and all-cause mortality by eGFR
values, independently of conventional and new risk factors. Analyses were
NT-proBNP, eGFR and Cardiovascular Mortality
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performed using strata of eGFR. In order to assess the role of NT-proBNP on the
association of eGFR with respect to mortality, all models were adjusted for age,
sex, diabetes duration (model 1), hypertension, HbA1c, logCRP, smoking, LDD-
cholesterol, logAER, CVD (model 2) and logNT-proBNP (model 3). Models were
constructed with variables as continuous measures to provide maximum power
for detecting an association between eGFR and mortality. In addition, we allowed
any of the following variables to enter the model if they add significantly or
modified HRs of NT-proBNP: antihyperglycemic treatment (diet, oral drugs,
insulin), treatment with ACE/ARB inhibitors, diuretics and other antihypertensive
treatment, statins, BMI, waist circumference, uric acid, total, HDL-cholesterol,
triglycerides, fibrinogen, systolic, diastolic and pulse blood pressure. We tested for
linear trends across eGFR strata by entering a single ordinal term into the Cox
regression model. The proportional hazard assumptions of explanatory variables
were assessed on the basis of Schoenfeld residuals. The likelihood ratio (LR) test
was used to assess the statistical significance of examined variables in nested
models. A P value of less than 0.05 was considered to indicate statistical
significance. We also assessed discrimination, that is the ability to separate
diabetic people of the Casale Monferrato cohort who will die and those who will
survive during the 6-years follow-up period, through C-statistic, which can range
from 0.5 (no predictive ability) to 1 (perfect discrimination). In our analysis, the
C statistic shows the proportion of pairs for which the model assigns higher
probability to the person who has died than to the person who has survived. We
additionally investigated the integrated discrimination improvement (IDI).
Reclassification of participants was assessed by categorical net reclassification
improvement (NRI) into risk categories of the cumulative risk of cardiovascular
death (,33%, 33–66% and.66%) [16]. Analyses were performed with STATA
software, version 10.0.
Results
As compared to the all cohort, patients included in the present study were
younger (67.8¡10.4 vs 70.6¡12.2 years, p,0.0001), had slight lower diabetes
duration (10.8¡7.9 vs 11.3¡8.4 years, p50.02) and negligible lower HbA1c
values (7.0%¡1.8 vs 7.2%¡1.7, 53 mmol/mol¡19.7 vs 55¡19.7, p50.05), but
similar systolic (146.0¡16.1 vs 145.2¡17.5 mmHg, p50.28) and diastolic
(82.7¡8.2 vs 83.1¡8.2 mmHg, p50.18) blood pressure levels. At the baseline
examination, most of subjects (64.5%) were elderly, being 65 years and over at
recruitment.
The baseline features of the cohort by categories of eGFR are shown in Table 1.
Log-NT-proBNP and eGFR values were negatively correlated (r520.28, p,0.0001).
During the 6-years follow-up period, 327 people died out of 8334.5 person-
years. Numbers of deaths for decreasing eGFR stratum were 111, 176, and 40,
respectively. CV mortality accounted for 149 (45.6%) deaths and out of them 90
deaths occurred in subjects without pre-existing CVD.
NT-proBNP, eGFR and Cardiovascular Mortality
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Compared to people with eGFR $90 ml/min/1.73 m2, those with eGFR of
60–89 ml/min/1.73 m2 had HR for CV mortality of 1.31 (0.99–1.88) and those
with values of 45–59 ml/min/1.73 m2 HR of 1.86 (1.23–2.83), independently of
age, sex, and diabetes duration (Table 2, model 1). Further adjustment for other
risk factors, slightly modified HRs (model 2). After inclusion of logNT-proBNB
into the fully adjusted model (model 3), however, HRs of eGFR decreased to non
significant values, whereas HR for logNT-proBNP was 1.84 (1.52–2.22). Results
were similar including in models eGFR as continuous rather than categorical
variable. No changes in HRs were observed after the inclusion into the model of
BMI, antidiabetic treatments, pulse pressure and treatment with ACE/ARB,
diuretics, statins.
As regards to all-cause mortality, HRs of eGFR were not significant in all
models, whereas logNT-proBNP was significant even in the fully adjusted model
3.
We then examined the discrimination effect of adding NT-proBNP measure-
ment to eGFR, classical cardiovascular risk factors and AER, comparing models
Table 1. Characteristics of people with type 2 diabetes in the Casale Monferrato Study with NT-proBNP assessment at the baseline examination (2000), by
estimated glomerular filtration rate (eGFR)
eGFR ml/min/1.73 m2
$90 (n5716) 60–89 (n5777) 45–59 (n5152) p value
Age (years) 63.3¡10.6 69.9¡9.0 74.0¡8.5 ,0.001
Males (%) 385 (53.8%) 378 (48.6%) 55 (36.2%) ,0.001
Duration of diabetes (years) 9.4¡7.3 11.1¡7.9 12.8¡8.5 ,0.001
BMI (kg/m2) 29.2¡5.5 28.3¡4.8 28.6¡5.5 0.02
HbA1c (%) 7.1¡1.8 6.8¡1.7 7.2¡1.8 ,0.001
CRP a (mg/l) 2.7 (1.2–6.0) 2.7 (1.2–5.7) 3.5 (1.6–8.0) ,0.001
Total Cholesterol (mmol/l) 5.44¡1.05 5.56¡1.02 5.55¡1.01 0.09
LDL-cholesterol (mmol/l) 3.28¡0.87 3.37¡0.89 3.32¡0.86 0.04
HDL-cholesterol (mmol/l) 1.41¡0.38 1.45¡0.40 1.44¡0.37 0.01
Triglycerides (mmol/l)a 1.42 1.43 1.57 ,0.001
ApoA1 (mg/dl) 155.3¡38.0 157.0¡38.2 158.4¡36.3 0.06
ApoB (mg/dl) 101.5¡26.7 102.8¡26.2 107.5¡29.0 0.11
ApoB/apoA1 0.71¡0.32 0.71¡0.31 0.73¡0.35 0.41
Fibrinogen (g/l) 3.7¡0.7 3.8¡0.7 4.0¡0.8 0.001
Uric acid (mmol/l) 297.40¡77.32 344.98¡118.96 130.67¡83.27 ,0.001
Systolic blood pressure (mmHg) 144.6¡16.0 146.2¡15.6 149.1¡17.6 ,0.001
Diastolic blood pressure (mmHg) 82.5¡8.4 82.6¡7.6 83.5¡8.6 0.73
Hypertension (%) 610 (85.4%) 713 (91.8%) 145 (95.4%) ,0.001
CVD (%) 124 (17.3%) 175 (22.5%) 44 (29.0%) ,0.001
AER (mg/min) 20–200 166 (27.7%) 151 (23.5%) 33 (27.3%) ,0.001
.200 19 (3.2) 33 (5.1%) 14 (11.6%)
NT-proBNP (pg/ml) a 56.0 (25–120) 102.3 (48–221) 182.3 (94–347) ,0.001
ageometric mean and interquartile range.
doi:10.1371/journal.pone.0114855.t001
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with and without NT-proBNP. The C-statistic pointed out a small advantage in
using NT-proBNP for cardiovascular mortality: 0.79 (95% CI 0.76–0.83), and
0.83, (95% CI 0.81–0.87) without and with NT-proBNP, respectively. The NRI
and the IDI were 0.44 (p50.016) and 0.03 (p50.02), respectively.
Discussion
Our prospective analysis of the population-based Casale Monferrato Study
provides evidence that, in type 2 diabetic patients with moderately reduced renal
function, the enhanced risk of CV mortality associated with eGFR is mainly
explained by increased plasma values of NT-proBNP, which were strongly
associated with mortality, even after multiple adjustments, including AER and
CRP. Indeed, when we analysed in a multivariate model the contribution of eGFR
and NT-proBNP, independently of each other and of other CV risk factors, we
provided evidence that NT-proBNP values were strongly associated with CV
mortality, whereas the well-known association with eGFR disappeared [17].
This finding indicate that NT-proBNP is either a confounder or a risk factor
explaining the association between eGFR and mortality in these patients. The
interpretation of increased values of NT-proBNP in asyntomatic people with
reduced eGFR is a matter of controversy, as in patients with CKD NT-proBNP are
Table 2. Results of Cox-regression analysis of variables associated with 6-years all-cause and cardiovascular mortality in people with type 2 diabetes of the
Casale Monferrato Study.
Model 1 Model 2 Model 3
Cardiovascular mortality
HR (95% CI) HR (95% CI) HR (95% CI)
eGFR ml/min/1.73 m2
90+ 1.00 1.00 1.00
60–89 1.31 (0.99–1.80) 1.74 (1.08–2.82) 1.42 (0.83–2.42)
45–59 1.86 (1.23–2.83) 1.95 (1.03–3.68) 1.22 (0.59–2.51)
p value for trend ,0.001 0.02 0.49
logNT-proBNP 1.84 (1.52–2.22)
All-cause mortality
HR (95% CI) HR (95% CI) HR (95% CI)
eGFR ml/min/1.73 m2
90+ 1.00 1.00 1.00
60–89 1.08 (0.88–1.33) 1.26 (0.95–1.67) 1.09 (0.79–1.50)
45–59 1.36 (1.01–1.83) 1.19 (0.78–1.82) 0.93 (0.50–1.49)
p value for trend 0.06 0.22 0.94
logNT-proBNP 1.51 (1.33–1.70)
Data are shown as hazard ratios (HRs) and 95% confidence intervals (95% CI).
HRs were independent of each other.
Model 1: adjusted for age, sex and diabetes duration;
Model 2: adjusted for model 1 adjustments plus HbA1c, LDL-cholesterol, hypertension, smoke, logCRP, logAER, CVD
Model 3: adjusted for model 2 adjustments plus logNT-proBNP.
doi:10.1371/journal.pone.0114855.t002
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typically elevated and few prognostic data are available. However, in the present
report we point out that increased plasma NT-proBNP values have a role per se,
which do not reflect diminished renal clearance of natriuretic peptides. The
prognostic impact of NT-proBNP is preserved even in diabetic patients with eGFR
60–89 ml/min/1.73 m2 compared to those with higher values, and appear to fully
explain the association between eGFR and CV mortality. Indeed, in a fully
adjusted model, the statistical significance of HR for eGFR disappeared, whereas
HR for NTproBNP was not modified. It is likely that NT-proBNP integrate the
information provided by several other risk factors associated with moderate
reduction of renal failure, such as arterial stiffness and volume overload, allowing
a better definition of individual risk. Although NT-proBNP is inactive, it is
secreted in equimolar concentrations with BNP, which, as recently reviewed [6],
has emerged as key mediators in the control of metabolic processes, including the
heart in the network of organs that regulate energy usage and metabolism.
Epidemiological studies have shown that natriuretic peptides are reduced in
people with obesity, insulin-resistance, diabetes and this deficiency may
contribute to enhance their global cardiovascular risk [6]. Therefore, it is now
evident that BNP/NT-proBNP can provide quantitative information about the
state of cardiovascular health across the all spectrum of CVD, with relevant
clinical implications.
Our findings are consistent and expand results from the few studies examining
the intertwined effects of NT-proBNP, renal dysfunction, and albuminuria on CV
mortality. The PREVEND study, performed on a large cohort of non-diabetic
subjects, has shown that NT-pro-BNP levels were associated with CV both
incident events and mortality even after adjustment for eGFR and albuminuria
[10]. However, NT-proBNP cut-off value was greater than in our study. A recent
prospective cohort study nested within the Trial to Reduce Cardiovascular Events
With Aranesp Therapy (TREAT) has reported that troponin T and NT-proBNP
enhance prediction of ESRD outcomes, including death, beyond established risk
factors, eGFR, and proteinuria in type 2 diabetic patients with CKD and anaemia
[18]. However, the study was nested within a randomized clinical trial, median
NT-proBNP were relatively elevated due to the more advanced stage of CKD of
recruited patients, and no separate analysis was performed for CV mortality that
was under-represented. Therefore, our study is the first to assess the prognostic
value of NT-proBNP for CV mortality in relation to eGFR and albuminuria in a
large population-based cohort of type 2 diabetic patients.
In subjects with decreased renal function the use of NT-proBNP has been
debated on the assumption that NT-proBNP levels may falsely increase because of
reduced renal NT-proBNP clearance with advancing CKD [9]. However, it has
been shown that renal fractional extraction for NT-proBNP diminishes only
modestly across a range of eGFRs and correlates minimally with eGFR [9]. Our
data on the superior prognostic impact of moderately elevated NT-proBNP values
with respect to eGFR values in diabetic patients with moderately impaired renal
function would support the clinical usefulness in routine practice of this marker.
We have recently suggested that NT-proBNP might have a relevant role in early
NT-proBNP, eGFR and Cardiovascular Mortality
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identification of type 2 diabetic patients at increased CV risk as in the Casale
Monferrato cohort a slight increase in NT-proBNP levels was a strong
independent predictor of CV mortality even in patients without pre-existing CVD
[7]. The present study strengthens this argument by showing that NT-proBNP
also explain at least in part the predictive effect of eGFR on CV mortality. The
underlying pathophysiology remains unclear; however, natriuretic peptides and
NT-proBNP are likely to directly reflect the subclinical cardiac damage from silent
myocardial ischemia, left ventricular hypertrophy, or increased apoptosis that
impacts on CV mortality and is often associated with moderately reduced renal
function [6].
Strengths of this study are the prospective design; the recruitment of a large
population-based cohort of type 2 diabetic people, increasing both precision and
generalizability; the centralized assessment of CV risk factors and biomarkers,
allowing to analyze the potential confounding effect of covariates; the high degree
of completeness of follow-up data. There are, however, certain limitations. Only
50.6% of patients of the original population-based cohort were recruited in the
study and they were younger than unrecruited people. As age was positively
correlated with NT-proBNP, the association between eGFR and mortality might
have been even greater in the entire cohort. Our results are based on an
observational prospective cohort and, though multivariate methods of analyses
were used to control for the effect of known confounders in the relationship
between NT-proBNP and mortality, we cannot rule out the possibility of residual
or undetected confounding effects on our results. A single NT-proBNP
measurement was performed using stored samples collected at baseline. Although
the stability of NT-proBNP after long term storage is unknown, all samples were
treated and stored under the same conditions. The study is based on a cohort of
mainly elderly subjects and, though this is a group of considerable clinical interest
because they constitute a high-risk group in whom traditional risk factors become
less predictive [19], our results need further confirmation in similar middle-aged
populations. Finally, no data on structural and functional cardiac abnormalities
were available.
In conclusion, this population-based study shows that in people with type 2
diabetes a moderate reduction in renal function increased 6-year CV mortality
independently of albuminuria. The association between eGFR and mortality,
however, was explained by the effect of NT-proBNP, which was a stronger
independent predictor of CV mortality, even in the earlier stage of CKD. Further
studies are warranted to assess if combining AER with NT-proBNP rather than
with eGFR may improve CV risk stratification in type 2 diabetic patients as well as
in the general population.
Supporting Information
S1 Data. File of baseline data.
doi:10.1371/journal.pone.0114855.s001 (DTA)
NT-proBNP, eGFR and Cardiovascular Mortality
PLOS ONE | DOI:10.1371/journal.pone.0114855 December 11, 2014 9 / 11
Author Contributions
Conceived and designed the experiments: GB. Performed the experiments: FB AL.
Analyzed the data: GB. Contributed reagents/materials/analysis tools: GG PCP.
Wrote the paper: GB GG.
References
1. Reutens AT (2013) Epidemiology of diabetic kidney disease. Med Clin North Am 97: 1–18.
2. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, et al. (2012) Associations of kidney
disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a
meta-analysis. Lancet 380: 1662–73.
3. Amin AP, Whaley-Connell AT, Li S, Chen S-C, McCullough PA, et al. (2013) The synergistic
relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD
or death in patients with diabetes: Results from the kidney early evaluation program (KEEP) Am J Kidney
Dis 61 (suppl. 2): S12–S23.
4. Delles C, Jardine AG (2011) Renal function and cardiovascular events: relevance of eGFR and
albuminuria in patients with diabetes. Diabetologia 54: 4–6.
5. Echouffo-Tcheugui JB, Kengne AP (2012) Risk models to predict chronic kidney disease and its
progression: a systematic review. PLoS Med 9: e1001344.
6. Gruden G, Landi A, Bruno G (2014) Natriuretic peptides, heart, and adipose tissue: new findings and
future developments for diabetes research. Diabetes Care 37: 2899–2908.
7. Bruno G, Landi A, Barutta F, Ghezzo G, Baldin C, et al. (2013) NH2-terminal pro-brain natriuretic
peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion
rate in elderly patients with type 2 diabetes: the Casale Monferrato population-based study. Diabetes
Care 36: 2677–82.
8. Das SR, Abdullah SM, Leonard D, Drazner MH, Khera A, et al. (2008) Association between renal
function and circulating levels of natriuretic peptides (from the Dallas Heart Study). Am J Cardiol 102:
1394–8.
9. DeFilippi C, van Kimmenade RR, Pinto YM (2008) Amino-terminal pro-B-type natriuretic peptide
testing in renal disease. Am J Cardiol 101: 82–8.
10. Scheven L, de Jong PE, Hillege HL, Lambers Heerspink HJ, van Pelt LJ, et al. (2012) High-sensitive
troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events
despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur Heart J 33:
2272–81.
11. Bruno G, Merletti F, Bargero G, Melis D, Masi I, et al. (2008) Changes over time in the prevalence and
quality of care of type 2 diabetes in Italy: the Casale Monferrato Surveys, 1988 and 2000. Nutr Metab
Cardiovasc Dis 18: 39–45.
12. Bruno G, Fornengo P, Novelli G, Panero F, Perotto M, et al. (2009) C-reactive protein and 5-years
survival in type 2 diabetes: the Casale Monferrato Study. Diabetes 58: 926–33.
13. Pagano E, Gray A, Rosato R, Gruden G, Cavallo Perin P, et al. (2013) Prediction of mortality and
macrovascular complications in type 2 diabetes: validation of the UKPDS Outcomes Model in the Casale
Monferrato survey, Italy. Diabetologia 56: 1726–34.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to
estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet
in Renal Disease Study Group. Ann Intern Med 130: 461–70.
15. Gruden G, Barutta F, Chaturvedi N, Schalkwijk C, Stehouwer CD, et al. (2012) N-terminal Pro-Brain
Natriuretic Peptide is associated with diabetic complications in the EURODIAB Prospective
Complications Study: the role of Tumor Necrosis Factor-a. Diabetes Care 35: 1931–36.
NT-proBNP, eGFR and Cardiovascular Mortality
PLOS ONE | DOI:10.1371/journal.pone.0114855 December 11, 2014 10 / 11
16. Pencina MJ, D’Agostino RB, Pencina KM, Janssens AC, Greenland P (2012). Interpreting
incremental value of markers added to risk prediction models. Am J Epidemiol 176: 473–81.
17. Bruno G, Merletti F, Bargero G, Novelli G, Melis D, et al. (2007) Estimated glomerular filtration rate,
albuminuria and mortality in type 2 diabetes: the Casale Monferrato Study. Diabetologia 50: 941–8.
18. Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, et al. (2011) Association between cardiac biomarkers
and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney
Dis 58: 717–28.
19. Kannel WB (2002) Coronary heart disease risk factors in the elderly Am J Geriatr Cardiol 11: 101–7.
NT-proBNP, eGFR and Cardiovascular Mortality
PLOS ONE | DOI:10.1371/journal.pone.0114855 December 11, 2014 11 / 11
